Lancashire and South Cumbria
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents:
mlcsu.lscformulary@nhs.net
.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-08-01 Wilsons disease
Penicillamine
Formulary
Tablets 125mg, 250mg
LSCMMG: Penicillamine shared care guideline
Links
LSCMMG shared care guideline - penicillamine
LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement
LSCMMG: Gluten-Free food products: Position Statement
LSCMMG: Oral Nutritional Supplements in Primary Care
LSCMMG: Penicillamine shared care guideline
LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
Medicines for children: Carnitine for metabolic disorders
NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
NICE HST23 Asfotase alfa for treating paediatric-onset hypophosphatasia
NICE HST26 Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency
NICE NG20: Coeliac disease: recognition, assessment and management
NICE NG203: Chronic kidney disease: assessment and management
NICE TA 915:Pegunigalsidase alfa for treating Fabry diease
NICE TA1020: Eplontersen for treating hereditary transthyretin-related amyloidosis
NICE TA821: Avalglucosidase alfa for treating Pompe disease
NICE TA821: Avalglucosidase alfa for treating Pompe disease
NICE TA868 Vutrisiran for treating hereditary transthyretin-related amyloidosis
NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis
NICE TA915: Pegunigalsidase alfa for treating Fabry disease
NICE: Asfotase alfa for treating paediatric-onset hypophosphatasia
Key
Full Site